Non-alcoholic fatty liver disease (NAFLD) is the leading cause of chronic liver disease and
considered a liver manifestation of metabolic syndrome. It is in close relationship with insulin …

Introduction Coronavirus disease 2019 (COVID-19) is a newly recognized infectious disease
that has spread rapidly. COVID-19 has been associated with a number of cardiovascular …

The sacubitril/valsartan combination is an important agent used in the treatment of heart
failure with reduced ejection fraction (HFrEF). Pulmonary artery stiffness (PAS) is an index …

Background and aims Familial hypercholesterolemia (FH) is a common genetic disease of
high-level cholesterol leading to premature atherosclerosis. One of the key aspects to …

Objectives The Model for End-stage Liver Disease excluding the international normalised
ratio that is derived from prothrombin time which is calculated as a ratio of the patient’s …

Objective: Heart failure (HF) is a growing public health problem with high morbidity and
mortality. Recently, angiotensin receptor neprilysin inhibitor (ARNi) has emerged as a promising …

Background: Blood viscosity is a strong predictor of cardiovascular events. However, the
relationship between blood viscosity and acute arterial occlusion (AAO) has not been studied …

Introduction In the early stage of the Fabry disease, diastolic dysfunction can occur before
left ventricular hypertrophy (LVH). Cardiovascular complications, most of which are seen as …

Objective: Although the prevalence and rate of myocardial infarction with non-obstructive
coronary arteries (MINOCA) are higher in women than in men in previous cohorts, potential …

Inadequate expansion of coronary stents is associated with stent thrombosis in early stage
and with stent restenosis in later stages. Postdilatation (postD) performed using non-…